Sugi Predict

Sugi Predict / Compounds / SCHEMBL3276372

SCHEMBL3276372

SCHEMBL3276372

ClCc1ccc2ccc(Cl)cc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 1/20 0.47
▸ PDE10A Q9Y233 1/20 0.43
▸ HTR3E A5X5Y0 1/20 0.41
▸ HTR3B O95264 1/20 0.41
▸ HTR3A P46098 1/20 0.41
▸ HTR3D Q70Z44 1/20 0.41
▸ HTR3C Q8WXA8 1/20 0.41
▸ DYRK1A Q13627 2/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ F7 P08709 1/20 0.38
▸ F3 P13726 1/20 0.38
▸ PIK3CG P48736 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ LOXL2 Q9Y4K0 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ CMA1 P23946 1/20 0.36
▸ AHR P35869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412433 0.86 HDAC1 (0.47) NR4A2PDE10AHTR3ADYRK1ANOS1
SCHEMBL1911781 0.82 NR4A2 (0.46) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL4348088 0.82 LOXL2 (0.47) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL7809623 0.82 S1PR4 (0.49) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL203068 0.82 CCR1 (0.48) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL28887330 0.82 S1PR4 (0.49) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL13878246 0.82 NR4A2 (0.46) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL29518426 0.82 CCR1 (0.48) NR4A2PDE10AHTR3EHTR3BHTR3A
SCHEMBL6088485 0.79 KMT2A (0.41) PDE10ADYRK1AHRH3GFERKMT2A
SCHEMBL27350783 0.79 PDE10A (0.46) NR4A2PDE10AHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961733-B1 METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2014-08-20 — — EP disclosed
CN-101370765-B Method for selectively producing primary amine SUMITOMO CHEMICAL CO 2013-03-13 — — CN disclosed
US-8329727-B2 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment GILEAD SCIENCES, INC. (US) 2012-12-11 — — US disclosed
US-8329727-B2 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment GILEAD SCIENCES, INC. (US) 2012-12-11 — — US disclosed
US-8269044-B2 Method for selectively producing primary amine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-18 — — US disclosed
US-7825254-B2 Heteroaromatic quinoline compounds PFIZER INC. (US) 2010-11-02 — — US disclosed
US-7790730-B2 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation GILEAD SCIENCES, INC. (US) 2010-09-07 — — US disclosed
US-7790730-B2 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation GILEAD SCIENCES, INC. (US) 2010-09-07 — — US disclosed
EP-1841757-B1 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PFIZER PROD INC (US) 2010-06-30 — — EP disclosed
US-20100028301-A1 IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2010-02-04 — — US disclosed
EP-0434827-A1 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-07-03 — — EP disclosed
EP-0414019-A2 Subsituted N-(quinolin-2-yl-methoxy)benzylsulfonylureas BAYER AG (DE) 1991-02-27 — — EP disclosed
WO-1991001123-A2 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? RORER INTERNATIONAL (OVERSEAS) INC. (US) 1991-02-07 — — WO disclosed
US-4977162-A Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments RORER PHARMACEUTICAL CORPORATION (US) 1990-12-11 — — US disclosed
CN-1045778-A (quinolin-2-ylmethoxy) phenyl-N that replaces, N '-sulfonylurea, its preparation method and the application in medicine thereof BAYER AG (DE) 1990-10-03 — — CN disclosed
EP-0387610-A2 Substituted (quinolin-2-yl methoxy)phenyl-N,N'-sulphonyl ureas, processes for their preparation and their use in medicines BAYER AG (DE) 1990-09-19 — — EP disclosed
US-4920131-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 — — US disclosed
US-4918081-A Quinoline derivatives and use thereof as antagonists of leukotriene d4 RORER PHARMACEUTICAL CORP. (US) 1990-04-17 — — US disclosed
WO-1989012629-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-12-28 — — WO disclosed
EP-0348155-A1 Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1989-12-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028301-A1 IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT CYP3A5, TPMT, ZC3HAV1 NR4A2 2280/4885PDE10A 973/4885HTR3E 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.